Why is the Medibank share price struggling to gain ground in May?

We check what's going on with shares in the private health insurer.

| More on:
retirement investing represented by older investor looking concerned at computer screen

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Medibank share price has moved in circles since the beginning of May
  • Weak market sentiment and volatility have dragged down the company's shares
  • Medibank reaffirmed its FY22 outlook at the Macquarie Australia Conference

The Medibank Private Ltd (ASX: MPL) share price has failed to make a move in the past three weeks.

Despite the company delivering a positive update at the Macquarie Australia Conference earlier this month, Medibank shares are travelling sideways.

For the recent period, Medibank shares are fetching just one cent more than they did at market close on 29 April.

Today, the private health insurance company's shares closed at $3.21, down 0.93% for the day.

What's happened to the Medibank share price in May?

Amid recent broader market weakness, the Medibank share price has been weighed down regardless of the company reaffirming its FY22 outlook.

Management noted in its latest presentation that private health insurance participation growth remains strong. This is due to more people continuing to prioritise their health and wellbeing, the company said.

Notably, Medibank Private has recorded six consecutive quarters of industry policyholder growth.

New-to-industry and younger groups are becoming major contributors to growth which are positive signs for industry sustainability.

Medibank stated it's on track to achieve 3.1% to 3.3% of policyholder growth in FY22.

Furthermore, the underlying average net claims expense per policy unit is forecast to be around 2.3% among resident policyholders.

The company advised it will deliver $15 million in productivity savings. In total, management expenses are predicted to come in at roughly $530 million for the full year.

Is this a buying opportunity?

One broker weighed in on the Medibank share price at the start of this month.

The team at Macquarie cut its 12-month price target by 1.5 % to $3.20 for Medibank shares.

It appears analysts have a similar view to investors' perceived value of the company's shares.

Looking further back, Citi has the most bullish outlook for the private health insurer's shares, upgrading them to a buy.

The broker also raised its rating by 4.3% to $3.65 per share following the company's half year results.

Based on today's price, this implies a potential upside of around 13.7%.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

This stock has made millions for investors over just a few months.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

Has the Pro Medicus share price risen too high too quickly?

Pro Medicus shares have rocketed 173% since this time last year.

Read more »